Australia
Dr John Prendergast will showcase the potential of New Synthetic Antibiotics
Clinical stage cannabinoid company Botanix Pharmaceuticals Limited is pleased to announce the receipt of firm commitments in respect of a A$40m placement led by specialist US-based biotech investment funds and leading US institutional investors, as well as the appointment of two new experienced dermatology executives.
Companies from across the globe share business and pipeline updates.
CelGro® Human Nerve Regeneration Trial Recently Orthocell announced that the first four patients successfully completed participation in the CelGro® nerve regeneration clinical trial.
The opening of a new $11.5m biotech production and training facility at the University of Technology Sydney has been welcomed by government and industry leaders who say fostering and keeping local talent in the burgeoning Life Sciences sector is key to building a globally competitive industry.
Mr Vince Ippolito, a US-based dermatology industry leader with over 30 years of pharmaceuticals experience, appointed as Executive Chairman of Botanix Pharmaceuticals
New data has shown that a new drug candidate from Botanix’s cannabidiol antimicrobial platform has potent activity against hypervirulent strains of the bacteria Clostridium difficile
Prescient Therapeutics Limited, a clinical stage oncology company, announced the start of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in Australia.
Recce Pharmaceuticals Ltd, the company developing a new class of synthetic antibiotics, announced that Dr John Prendergast has been appointed to Independent Chair with founder Dr Graham Melrose stepping back from the role of Executive Chair to Executive Director and Chief Research Officer.
Imugene Limited, a clinical stage immuno-oncology company, announced new clinical data from the Phase Ib study of its HER-Vaxx cancer vaccine showing cancer fighting antibody and clinical response rates continue to be positive in the patients receiving the optimal biological dose of vaccine.
PRESS RELEASES